Report : Asia Pacific PCR for Respiratory Infection Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Real-Time PCR (qPCR), Multiplex PCR, Traditional PCR, Digital PCR, Reverse-Transcriptase (RT-PCR), and Others), Product Type (Reagents & Kits, Instruments, and Others), Infection Type (Bacterial Infections, Viral Infections, and Fungal & Other Pathogens), and End User (Hospitals, Physician Clinics, Clinical Laboratories, Academic & Research Institutions, Biotech & Pharma Companies, and Others)
The real-time PCR (qPCR) segment by type is estimated to lead the market growth during the forecast period.
According to a new market research study of “Asia Pacific PCR for Respiratory Infection Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis by Type, Product Type, Infection Type, End User and Country.” The Asia Pacific PCR for respiratory infection diagnostics market is expected to reach US$ 1,515.94 million by 2028 from US$ 737.47 million in 2021; it is estimated to grow at a CAGR of 10.8% from 2021 to 2028. The report highlights trends prevailing in the Asia Pacific PCR for respiratory infection diagnostics market and the factors driving market along with those that act as hindrances. The growth of the market is determined due to some of the key driving factors, such as increasing burden of chronic respiratory diseases (CRDs) and growing developments in PCR testing, are expected to propel the growth of the market. However, availability of alternative assays is the major factor hindering the market growth.
PCR has become an indispensable tool for various clinical and diagnostic applications or examinations due to continuous research & development on PCR technologies. Therefore, it offers many opportunities for rapid point-of-care diagnostics for various infectious diseases. For instance, F. Hoffmann-La Roche Ltd is continuously working on the advancements of dPCR techniques. Digital PCR (dPCR) has extended its applications to the clinical field and has emerged as an important clinical tool. dPCR offers ultrasensitive and absolute nucleic acid quantification without reference standard. Thus, it offers a broader aspect for standardizing and comparing results between laboratories. In addition, rising incidence of target infectious diseases and genetic disorders; increasing investments, funds, and grants; and growing utilization of biomarker profiling for disease diagnostics are among other factors that are likely to make PCR an indispensable tool for the future. In addition, PCR testing is significantly used in institutions such as nursing homes, chronic care facilities, and hospitals for identifying influenza virus infection that causes respiratory outbreaks. Therefore, various companies are offering PCR kits that can detect the presence of pathogens causing respiratory diseases. Apart from the increasing incidence of acute and chronic respiratory diseases, other factors such as environmental and climatic conditions, air pollution, and discoveries of novel bacteria, viruses, and pathogens are likely to serve as vital growth opportunities for PCR testing for respiratory infection diagnostics in the coming future.
COVID-19 pandemic has widely affected the economies in the Asia Pacific region. The rising occurrence COVID-19 cases results in increased stress on the region's healthcare system, which is also rising the demand for diagnostic tests in the healthcare system, supporting the expansion of the sector in this region. Hence, countries such as India, China, and South Korea have increased their capacities to conduct PCR testing. Several manufacturers are developing advanced PCR test kits and systems for the detection of COVID-19 virus. Also, high throughput molecular testing is expected to play a central role in the future management of the COVID-19 pandemic. Thus, such developments in the market are likely to foster the growth of market during the forecast period.
The Asia Pacific PCR for respiratory infection diagnostics market, by type, is segmented into real time PCR (qPCR), traditional PCR, reverse-transcriptase (RT-PCR), digital PCR, multiplex PCR, and others. Based on product type, the Asia Pacific PCR for respiratory infection diagnostics market is segmented into reagents and kits, instruments, and others. Based on infection type, the Asia Pacific PCR for respiratory infection diagnostics market is segmented into bacterial infection, viral infection, and fungal & other pathogens. The bacterial infection segment is further divided into bordetella, streptococcus pneumoniae, staphylococcus aureus, haemophilus influenzae, moraxella catarrhalis, mycoplasma pneumoniae, chlamydophila pneumoniae, legionella and others. Additionally, the viral infection segment is further bifurcated into rhinoviruses, influenza virus, severe acute respiratory syndrome (sars) cov-2 virus, respiratory syncytial virus (rsv), adenovirus, enterovirus, parainfluenza, human metapneumovirus (hmpv) and others. Further, based on end user, the Asia Pacific PCR for respiratory infection diagnostics market is segmented into hospitals, physician clinics, clinical laboratories, academic and research institutions, biotech and pharma companies, and others. Geographically, the Asia Pacific PCR for respiratory infection diagnostics market can be segmented into India, Japan, China, South Korea, Australia and Rest of Asia Pacific.
Abbott, F. HOFFMANN-LA ROCHE LTD, Hologic, Inc., BD, BIO-RAD LABORATORIES INC., bioMerieux SA, QIAGEN, Thermo Fisher Scientific Inc., and Seegene Incare among the leading companies operating in the Asia Pacific PCR for respiratory infection diagnostics market.
Contact Person: Sameer Joshi
Email Id: email@example.com